Merck & Co. announced successful Phase III results for its oral PCSK9 inhibitor, enlicitide decanoate, demonstrating significant reductions in LDL cholesterol across two key trials in patients with hyperlipidemia. The drug, administered once monthly, met primary and secondary endpoints, potentially entering a market dominated by injectable PCSK9 therapies. The company positions enlicitide as the first oral candidate suited for combination therapies and improved patient compliance.